Is Pacira BioSciences, Inc. (PCRX) overvalued? · P/E 174, rev $369.8M
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page asks whether Pacira BioSciences, Inc. (PCRX) looks expensive on cached numbers — not a short thesis.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
PCRX currently screens at market cap $890.8M and trailing P/E 174.2. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PCRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PCRX stock page for the full model, not this heading.
Not investment advice.